Gan & Lee Pharmaceuticals (603087.SH): The first subject in the United States Phase II clinical trial of Bovangluteptide (GZR18) injection completed dosing.
Gan Li Pharmaceutical Industry (603087.SH) announced that the company's independently developed Bofange peptide (research and development code: GZR18...
Gan & Lee Pharmaceuticals (603087.SH) announced that the company's self-developed Bo Fangelu peptide (research code: GZR18) injection is undergoing Phase II clinical trials in the United States, and recently successfully completed the dosing of the first trial subject.
It is reported that Bo Fangelu peptide (research code: GZR18) injection is a GLP-1RA administered every two weeks, aimed at treating weight management in adults with type 2 diabetes and obesity/overweight individuals. Currently, a Phase II clinical trial for the indication of obesity/overweight is taking place in the United States, making it the world's first single-target GLP-1RA drug to be compared head-to-head with liraglutide for weight loss efficacy.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
